Tests of fully oral drug regimens for hepatitis C showed they cured up to 95% of previously untreated patients but only 47% of those whose earlier therapy had failed, a University of Texas researcher reported. None of the patients were given pegylated interferon, which has been a standard HCV treatment but is difficult for patients to tolerate.

Related Summaries